pharmaceuticals
In a move that investors looking for more defensive ideas should applaud, the analysts at Goldman Sachs have added Bristol-Myers Squibb to the Americas Conviction List. Plus, here are four additional...
Published:
BioNTech was in the spotlight on Tuesday after it received a sizable price target hike from one key analyst.
Published:
Prevail Therapeutics shares absolutely exploded on Tuesday morning after it was announced that the company would be acquired by Eli Lilly.
Published:
Alexion Pharmaceutical shares shot up on Monday after it was announced over the weekend that the company would be acquired by AstraZeneca.
Published:
Rotating from overbought and crowded momentum stocks makes sense now. From a total return standpoint, dividend-paying large-cap pharmaceutical stocks may be one of the best ideas for 2021.
Published:
COVID-19 stocks were on the move on Wednesday after a few huge updates in regards to vaccine approval.
Published:
Here is an update on the stocks of each major player in the COVID-19 arena, including brief trading histories and consensus price targets.
Published:
Merck has joined the fight against COVID-19 by acquiring OncoIummune in an all-cash transaction.
Published:
Shares of COVID-19 vaccine duo Pfizer and BioNTech made handy gains on Wednesday after they announced their late-stage coronavirus study had concluded.
Published:
Moderna reported a 95.4% effectiveness rate for its COVID-19 vaccine. This is the second vaccine to hit more than 90% efficacy in the past week.
Published:
Pfizer and BioNTech stocks both exploded on Monday after these companies provided an update on their coronavirus vaccine.
Published:
Regeneron Pharma reported its third-quarter financial results before the markets opened on Thursday.
Published:
Merck and Pfizer reported their most recent quarterly results before the opening bell Tuesday, and investors were not thrilled about this quarter for these two pharmaceutical giants.
Published:
Clinical-stage biopharmaceutical company Atea Pharma intends to price 11 million shares for and intial public offering valued up to more than $303 million.
Published:
Are BioSpecific Technologies shareholders actually getting a good deal from the merger agreement with Endo International?
Published: